General Biologicals

General Biologicals EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of General Biologicals (4117.TWO) as of Oct 31, 2026 is -218.37 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -208.81 M TWD — a change of 4.58% (lower).

EBITDA

-218.37 MTWD

YoY

4.58%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of General Biologicals is 2025 -218.37 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of General Biologicals was 2024 -208.81 M TWD. It decreases by 4.58% lower compared to the previous year.

The General Biologicals EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-52.22 M TWD
Jan 1, 2019
-26.24 M TWD
Jan 1, 2020
49.34 M TWD
Jan 1, 2021
49.07 M TWD
Jan 1, 2022
-36.24 M TWD
Jan 1, 2023
-165.43 M TWD
Jan 1, 2024
-208.81 M TWD
Jan 1, 2025
-218.37 M TWD
The General Biologicals EBITDA history
YEAREBITDAYoY
-218.37 MTWD+4.58%
-208.81 MTWD+26.23%
-165.43 MTWD+356.49%
-36.24 MTWD-173.85%
49.07 MTWD-0.53%
49.34 MTWD-288.01%
-26.24 MTWD-49.75%
-52.22 MTWD-36.80%
-82.63 MTWD+5.83%
-78.08 MTWD-6.18%
-83.22 MTWD+171.57%
-30.65 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

General Biologicals Stock analysis

What does General Biologicals do? General Biologicals Corp., headquartered in Baoshan, Hsinchu, Taiwan, operates in the Health Care sector, specifically within the Biotechnology industry. The company engages in research, development, manufacturing, and trading of diagnostics, pharmaceuticals, and medical supplies. Its main products include detection reagents, biological protein new drugs, P113, and medical supplies, distributed domestically and internationally. Listed on 4 July 2002, the company employs 63 people. General Biologicals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about General Biologicals stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of General Biologicals is -218.37 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of General Biologicals changed from -208.81 M TWD to -218.37 M TWD, representing a 4.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) General Biologicals since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s General Biologicals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — General Biologicals

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — General Biologicals